With rising resistance to terbinafine, and consistently high MICs to fluconazole and griseofulvin, itraconazole is being increasingly used as a first line drug for tinea corporis/cruris. However, inadequate clinical responses are often seen with it in spite of in vitro susceptibility. This is possibly related to a variable pharmacokinetic profile of itraconazole. The drug serum levels associated with the therapeutic outcome have not been defined in dermatophytic infections.

中文翻译：

---

预测顽固性股癣和股癣中伊曲康唑的治疗截止血清水平——一项前瞻性试验

随着对特比萘芬耐药性的增加，以及对氟康唑和灰黄霉素的持续高 MIC，伊曲康唑正越来越多地用作治疗股癣/股癣的一线药物。然而，尽管在体外易感性，但经常看到不充分的临床反应。这可能与伊曲康唑的可变药代动力学特征有关。与治疗结果相关的药物血清水平尚未在皮肤癣菌感染中确定。